Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600K status confers therapeutic sensitivity to Vemurafenib in patients with Melanoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.